Back to search

Article

Pharmacokinetic bioequivalence between Nuvaring® (etonogestrel/ethinylestradiol 11.7/2.7 mg) and Ornibel Premium® (etonogestrel/ethinylestradiol 8.25/2.6 mg), a novel polymer composition contraceptive vaginal ring

2026-03-08

Abstract excerpt

<title>Abstract</title> <p>Objective: This study was a single-centre, randomized, single ring insertion, 2-period, 2-sequence, crossover study design to assess comparative bioavailability and therefore establish bioequivalence of 2 different products of ethinylestradiol/etonogestrel vaginal ring (delivering 0.015/0.12 mg per day) after a single vaginal ring is inserted and worn for 28 days in healthy female subje...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
c8b414f4-ec22-5037-b6e6-83a132230f86
DOI
10.21203/rs.3.rs-8601132/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Pharmacokinetic bioequivalence between Nuvaring® (etonogestrel/ethinylestradiol 11.7/2.7 mg) and Ornibel Premium® (etonogestrel/ethinylestradiol 8.25/2.6 mg), a novel polymer composition contraceptive vaginal ringDOI 10.21203/rs.3.rs-8601132/v1
Select a neighboring publication to make it the new centre.